BEVATAS 300 INJECTION

BEVATAS 300 INJECTION is a recombinant monoclonal antibody that belongs to the immunotherapy class of cancer treatment. It can either be used as monotherapy or in combination with chemotherapy or immunotherapy medications to improve the overall survival rate.

While for women with reproductive potential subjected to BEVATAS 300 INJECTION, it is advised to discuss with your doctor regarding the effective birth control methods during the treatment. Also to be continued for a minimum of 6 months after the treatment course completion as this medicine may impair fertility.

BEVATAS 300 INJECTION is associated with increased risk of bleeding complications and poor wound healing. Hence it is suggested to avoid planning for surgery and maintain an interval of 28 days before or after surgery.

All the side effects that are relatively caused by BEVATAS 300 INJECTION occur until the drug concentration stays in the body. It is found that this medicine will be contained in our body for almost 4 months after the final dose.

BEVATAS 300 INJECTION is given intravenously through infusion and the amount of drug will be measured based on the patient’s body weight, height and age. The first dose will be administered for 90 minutes and if well tolerated the infusion time can be reduced to 30 minutes.

Inform your physician before starting your treatment with BEVATAS 300 INJECTION in case, if you are pregnant or planning for pregnancy as this medicine may cause harm to the unborn baby and interrupt the formation of blood vessels.

You should inform your doctor about all the medicines you are currently taking, including prescription, over-the-counter medications, and herbal supplements, before starting treatment with BEVATAS 300 INJECTION. Your doctor will determine if there are any potential interactions.

It is vital to inform your physician before taking BEVATAS 300 INJECTION if you have the following conditions: conditions involving inflammation in the stomach (such as ulcer, colitis), experience allergic reactions to BEVATAS 300 INJECTION or its ingredients, have recently undergone surgery (as it is associated with the risk of bleeding), or have diabetes, hypertension, or heart problems.

The active ingredient in BEVATAS 300 INJECTION is Bevacizumab.

BEVATAS 300 INJECTION works by targeting a protein called VEGF (Vascular Endothelial Growth Factor), which is involved in the growth of new blood vessels that tumors need to grow and spread. By blocking VEGF, the injection helps slow down tumor growth and cut off their blood supply.

BEVATAS 300 INJECTION is used to treat certain types of cancers by slowing down the growth and spread of cancer cells.